Naturex has reported revenues up 18.2% and operating income up 19.3% compared with the previous year, describing the performance as ‘excellent’.
According to the company, its positive momentum over the full-year highlights the relevance of Naturex's business model that combines sustained organic growth with a dynamic strategy of acquisitions. The company also reaped benefits from its positions in both mature markets still active despite a difficult economic environment in Europe and in faster growing emerging markets that accounted for 17.7% of the annual revenue.
Product mix continued to improve as the share of high value-added products and concepts grew and made it possible to offset at the gross margin level the negative impact from the integration of Pektowin.
"While 2012 was sadly marked by the death of Naturex's founder, Jacques Dikansky, operating performances were altogether satisfactory in a year that otherwise included many positive achievements. The Group remained successful in generating revenue through its development strategy combining organic and external growth, while pursuing expansion in its different markets, particularly in emerging countries," said Naturex's Chairman CEO, Thierry Lambert. "We must further strengthen our long-term growth potential in 2013, in particular by intensifying our research and development efforts, and I am confident in the ability of Naturex and its teams to meet this challenge.”
